MarketPulse

chemotherapy

2 articles
BenzingaBenzinga··Vandana Singh

Baxter Cancer Drug Supply Crisis Compounds Earnings Weakness

Baxter faces EU cancer drug shortage extending to Q1 2027 amid disappointing 2026 earnings guidance, projecting $1.85-$2.05 EPS versus $2.25 consensus.
BAXearnings guidancesupply chain
BenzingaBenzinga··Vandana Singh

Bristol Myers Wins FDA Approval for Opdivo Combo in Untreated Hodgkin Lymphoma

Bristol Myers wins FDA approval for Opdivo plus chemotherapy in untreated Hodgkin lymphoma. Stock declined 1.33% despite clinical success in Study CA209-8UT.
BMYCELGrFDA approvalclinical trial